Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Accumulated Expenses: 2019-2024

Historic Accumulated Expenses for Eton Pharmaceuticals (ETON) over the last 6 years, with Dec 2024 value amounting to $8.9 million.

  • Eton Pharmaceuticals' Accumulated Expenses rose 18893.75% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year increase of 18893.75%. This contributed to the annual value of $8.9 million for FY2024, which is 65.50% up from last year.
  • Eton Pharmaceuticals' Accumulated Expenses amounted to $8.9 million in FY2024, which was up 65.50% from $5.4 million recorded in FY2023.
  • Eton Pharmaceuticals' 5-year Accumulated Expenses high stood at $8.9 million for FY2024, and its period low was $1.2 million during FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $5.4 million (2023), whereas its average is $6.0 million.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Accumulated Expenses fell by 15.71% in 2020, and later surged by 168.08% in 2022.
  • Yearly analysis of 5 years shows Eton Pharmaceuticals' Accumulated Expenses stood at $1.2 million in 2020, then rose by 16.75% to $1.4 million in 2021, then soared by 168.08% to $3.7 million in 2022, then surged by 47.08% to $5.4 million in 2023, then surged by 65.50% to $8.9 million in 2024.